Law and Regulations

Benjamin Jolley, PharmD, presents on recent developments regarding pharmacy benefit manager reform on the state and federal levels.

This episode highlights the landmark FTC settlement with Express Scripts and what independent pharmacies and plan sponsors can expect going forward.

With a key exemption under DSCSA expiring at the end of the year, Matt Sample from Cencora helps pharmacies understand the tools and processes they need now to best comply with the law.

Matt Sample, senior vice president of manufacturer, quality, and replenishment operations at Cencora, discusses DSCSA compliance hurdles, VRS tools, and a new push toward 12-digit NDCs.

In their continued fight against major health care corporations, Senators Elizabeth Warren and Josh Hawley are aiming to delink ownership among PBMs, insurers, and wholesalers.

Anne Cassity, senior vice president of government affairs at NCPA, discusses the next moves of both PBMs and community pharmacy advocates following the signing of HR 7148.

With President Trump’s signing of HR 7148, experts are now racing to get a grasp on the monumental shifts in pharmacy that will stem from this new legislation.

As lawmakers continue to deliberate on HR 7148, pharmacy law expert, Jesse Dresser, Esq, joined Drug Topics to discuss its provisions related to PBMs.

This episode explores important insights on PBM reform and what pharmacies can look out for throughout 2026.

In part 2, ASCP’s senior policy expert James Lewis breaks down the MTF system and how it is impacting the thousands of pharmacies that dispense Medicare-covered drugs.

Focused on lowering costs and saving patients money, the plan is focused on drug prices, insurance premiums, and some of health care’s largest companies.

This December 2025 order is an extension of HHS’ recommendation to reconsider marijuana as a Schedule III medication in 2023.

During his second term, President Trump has bolstered his approach at lowering prescription drug prices in the US through innovative yet unprecedented decisions.

A conversation with NCPDP’s Rick Sage explored the lasting effects on pharmacy stemming from the record-breaking government shutdown.

Researchers explore highly engaged social media posts related to glucagon-like peptide-1 receptor agonists, attention deficit/hyperactivity disorder stimulants, and autoimmune biologics.

This episode explores ongoing developments in pharmacy law, specifically for independent pharmacies and their representatives who attended the 2025 NCPA Convention & Expo.

In part 2 of a roundtable on the Most Favored Nation Executive Order for prescription drugs, experts gathered to discuss recent developments and how they’ll impact the policy’s future.

As shortages end, pharmacies that compound GLP-1s face lawsuits, stricter board oversight, and tougher FDA enforcement.

The panel discussion features pharmacy leaders, policy experts, and well-known legal minds discussing the Most Favored Nation drug policy and its overarching implications.

Researchers gathered a group of adolescent-serving clinicians and asked them about their confidence in helping patients with abortion access.

Senators Warner and Thune reintroduced the ECAPS legislation improving both seniors’ access to care and pharmacists’ ability to get reimbursed for clinical services.

Marta Wosinska, PhD, and Joey Mattingly, PharmD, MBA, PhD, joined Drug Topics to help us understand how pharmaceutical tariffs could potentially impact the pharmacy industry.

Greg Miller, RPh, discussed the past, present, and future of the Inflation Reduction Act and key insights pharmacists should understand in order to keep up with the legislation.

The order is set to make patients’ prescription costs similar to other nations with the lowest-priced drugs in the world.

At AAP 2025, Douglas Hoey, CEO of NCPA, discussed the possibility of PBM reform under the new administration and his take on Optum Rx’s plans to introduce a cost-plus reimbursement model.